Results 181 to 190 of about 280,401 (218)
Some of the next articles are maybe not open access.

Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy

Thyroid, 2021
Background: We report the therapeutic use of K1-70™, a thyrotropin receptor (TSHR) antagonist monoclonal antibody, in a patient with follicular thyroid cancer (FTC), Graves' disease (GD), and Graves' ophthalmopathy (GO).
Mabel Ryder   +9 more
semanticscholar   +1 more source

Immunological Aspects of Graves’ Ophthalmopathy

open access: yesBioMed Research International, 2019
The body's autoimmune process is involved in the development of Graves' disease (GD), which is manifested by an overactive thyroid gland. In some patients, autoreactive inflammatory reactions contribute to the development of symptoms such as thyroid ...
Alicja Głuszko   +2 more
exaly   +2 more sources

Evaluation of Retinal Neurodegeneration and Choroidal Thickness in Patients with Inactive Gravesʼ Ophthalmopathy

Klinische Monatsblätter für Augenheilkunde, 2021
Purpose The study was conducted for the assessment of the retinal nerve fiber layer, ganglion cell layer, and subfoveal choroidal thickness changes in patients with inactive Gravesʼ ophthalmopathy (GO) using swept-source optical coherence tomography (SS ...
M. Kurt   +4 more
semanticscholar   +1 more source

TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis

open access: yesJournal of Clinical Endocrinology and Metabolism, 2016
Christine C Krieger   +2 more
exaly   +2 more sources

Low signal intensities of MRI T1 mapping predict refractory diplopia in Graves’ ophthalmopathy

Clinical Endocrinology, 2020
In Graves’ ophthalmopathy (GO), fibrosis in extraocular muscles (EOMs) may be related to intravenous glucocorticoid (ivGC)‐resistant diplopia. Signal intensity (SI) of magnetic resonance imaging (MRI) T1 mapping can quantify properties of EOM components,
K. Matsuzawa   +11 more
semanticscholar   +1 more source

Outcome and Safety of Different Cumulative Doses and Protocols of Intravenous Methylprednisolone in Moderate to Severe and Active Graves’ Ophthalmopathy

Ophthalmologica Indonesiana, 2019
Background: Graves’ ophthalmopathy (GO), also known as Graves’ orbitopathy or thyroid eye disease, has a potential sight-threatening complications. The activity and severity are important determinants in GO and are implications for treatment. Intravenous Glucocorticoid (GC) was associated with significantly greater efficacy and
Amelya Permata Sari   +2 more
openaire   +1 more source

The expression of interleukin‐15 and interleukin‐17 in tears and orbital tissues of Graves ophthalmopathy patients

Journal of Cellular Biochemistry, 2019
The objective of this study was to study the levels of interleukin (IL)‐15 and IL‐17 in tears and orbital tissues of the patients with the Graves ophthalmopathy (GO) (active and inactive stages) and in controls.
Qun Chen
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy